What Baxter's Lobbyists Bent Congressional Ears About... Through 3/4ths of 2023, At Least.

Clearly, with its most recent 2023 organic revenue woes, and its overall smaller size (on revenue, market cap and profitability) compared to the others we've tracked. . . Baxter International has had to reduce its spend -- on lobbying.

But it still seeks favor in several of the usual buckets. Do see below:

. . .Issues related to pharmaceutical pricing; Legislation to incentivize new technology for innovation in home dialysis (no current bill number). . . .

Issues relating to drug pricing, home dialysis expansion, ESRD reimbursement for Hemodialysis; 340B Drug pricing, device sterilization; Issues relating to safe mobility and issues relating to diabetic retinopathy; Issues relating to pandemic all-hazards preparedness act; H. Res. 550 and H.R. 4421; Issues related to artificial intelligence in healthcare. . . .

Issues related to increasing funding for Strategic National Stockpile; Labor, Health, and Human Services appropriations. . . .

Taxation of multinational companies; Monitor tax reform proposal relating to corporate tax policies. . . .

Welp. We should note that Baxter has announced plans to spin-off to shareholders the renal / dialysis businesses, in a company to be called "Vantive" -- so the make up of this spend will change markedly, in 2024 and beyond. Legacy Baxter will be more a solutions, sets and pumps biz, by then. [With a few other niche bio-businesses, to be sure.]

NOW. . . we will call this series "done." [Unless a commenter pipes up to ask about some other life science company, that is.] Grin. Onward.

नमस्ते